Across TCGA pan-cancer cohorts, MIR1302-3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR1302-3 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MIR1302-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR1302-3 expression acts as an unfavorable survival marker.

LUAD and SARC are the cancer types where MIR1302-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.004	0.835	<.001	36	view →
SARC	OS	Median	All	0.241	0.766	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MIR1302-3 tumor-vs-normal RNA expression · all MIR1302-3 data types